163 related articles for article (PubMed ID: 37323057)
1. Expanded use of sodium-glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction.
Schoenborn EM; Skersick PT; Thrasher CM; Page RL
Pharmacotherapy; 2023 Sep; 43(9):950-962. PubMed ID: 37323057
[TBL] [Abstract][Full Text] [Related]
2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
Maltês S; Cunha GJL; Rocha BML; Presume J; Guerreiro R; Henriques C; Rodrigues C; Araújo I; Fonseca C
Cardiology; 2021; 146(2):201-206. PubMed ID: 33524984
[TBL] [Abstract][Full Text] [Related]
4. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.
Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M
Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
6. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin: A Review in Symptomatic Chronic Heart Failure.
Frampton JE
Drugs; 2022 Nov; 82(16):1591-1602. PubMed ID: 36374374
[TBL] [Abstract][Full Text] [Related]
8. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
Green JB; McCullough PA
Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
[TBL] [Abstract][Full Text] [Related]
10. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat.
Girerd N; Zannad F
J Intern Med; 2023 May; 293(5):550-558. PubMed ID: 36871279
[TBL] [Abstract][Full Text] [Related]
12. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
13. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
[No Abstract] [Full Text] [Related]
14. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
Nam K; Cho DS; Kim H; Kwon B; Yoon Y; Park C; Kim ES; Youn JC; Park SK
Clin Drug Investig; 2023 Jul; 43(7):463-474. PubMed ID: 37365452
[TBL] [Abstract][Full Text] [Related]
15. ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial).
Jariwala P; Jadhav K; Punjani A; Boorugu H; Mari AR
Indian Heart J; 2021; 73(5):605-611. PubMed ID: 34627577
[TBL] [Abstract][Full Text] [Related]
16. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
[TBL] [Abstract][Full Text] [Related]
17. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.
Jhalani NB
Adv Ther; 2022 Aug; 39(8):3472-3487. PubMed ID: 35699903
[TBL] [Abstract][Full Text] [Related]
18. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
Stolfo D; Lund LH; Benson L; Lindberg F; Ferrannini G; Dahlström U; Sinagra G; Rosano GMC; Savarese G
Eur J Heart Fail; 2023 Sep; 25(9):1648-1658. PubMed ID: 37419495
[TBL] [Abstract][Full Text] [Related]
19. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
[TBL] [Abstract][Full Text] [Related]
20. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.
Gonzalez J; Dave CV
BMC Cardiovasc Disord; 2024 May; 24(1):285. PubMed ID: 38816795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]